Modulating radiolabeling reaction conditions significantly reduces the chromatographic heterogeneity of technetium-99m labeled iPSMA while maintaining high radiochemical purity, according to an experimental investigation published in Frontiers in Nuclear Medicine. Researchers systematically investigated reaction parameters to address the challenge of multiple radiochemical species formed during the labeling of hydrazinonicotinamide-conjugated targeting vectors. By adjusting the reaction medium composition, the team demonstrated substantial improvements in species distribution and subsequently translated the findings into a single-vial cold-kit proof of concept.
Technetium-99m labeling of hydrazinonicotinamide-conjugated vectors typically requires transfer ligands and co-ligands, an arrangement that can generate multiple distinct radiochemical species exhibiting slight differences in their physicochemical and biological properties. To overcome this limitation, the authors sought to optimize the radiolabeling process for the prostate-specific membrane antigen ligand iPSMA. Their experimental goal centered on reducing chromatographic heterogeneity without compromising overall radiochemical purity, ultimately aiming to transfer the optimized protocol into a streamlined, freeze-dried cold-kit preparation.
The experimental methodology evaluated twenty distinct radiolabeling conditions across three replicates each. The researchers systematically and independently varied the selected co-ligand, transfer ligand, buffer system, reducing agent, antioxidant, reaction duration, and reaction temperature. Following the radiolabeling procedures, the reaction products were thoroughly characterized using radio-high-performance liquid chromatography and radio-thin-layer chromatography to assess radiochemical purity and profile the resulting distribution of radiolabeled species.
In baseline testing, the reference labeling protocol achieved a radiochemical purity of 90.31 ± 0.83 percent, with the predominant radiolabeled species accounting for 76.97 ± 2.53 percent of the total radiocomplexes. Across all tested variables, the composition of the reaction medium exerted the most decisive influence on chromatographic distribution. In particular, the choice of buffer played a critical role in controlling species uniformity throughout the radiochemical reaction.
Implementing an optimized buffer system of 0.2 molar sodium acetate at pH 7 in conjunction with ethylenediamine-N,N’-diacetic acid and tricine markedly enhanced labeling quality. Under these specific conditions, the overall radiochemical purity increased to 95.15 ± 0.29 percent, while the proportion of the predominant radiolabeled species rose to 96.21 ± 0.23 percent. Furthermore, levels of reduced or hydrolyzed technetium remained completely below the detection threshold of radio-thin-layer chromatography.
The optimized labeling parameters were subsequently evaluated in freeze-dried single-vial formulations examining five different bulking agents. During this translation phase, the team tested the impact of bulking agent content, technetium-99m activity levels, heating duration, and pertechnetate eluate age. Among the tested candidates, mannitol provided the best overall performance and was selected at an optimal concentration of 40 milligrams per vial for the formulation.
Under the finalized formulation parameters, satisfactory kit performance was achieved using up to 1.5 gigabecquerels of freshly eluted pertechnetate obtained within 30 minutes of elution. The resulting reconstituted preparation demonstrated 0.92 ± 0.11 percent residual pertechnetate, 91.47 ± 2.66 percent of the major radiolabeled species, and an overall radiochemical purity of 95.69 ± 1.28 percent.
The authors concluded that radio-HPLC-guided optimization effectively suppresses radiochemical heterogeneity while maintaining elevated radiochemical purity for technetium-99m labeled iPSMA. Although these results successfully demonstrate an all-in-one single-vial proof of concept, the researchers noted that further analytical, pharmaceutical, and biological development remains necessary prior to clinical implementation.
Subject of Research: Radiochemical optimization and single-vial cold-kit development for technetium-99m labeled iPSMA
Article Title: Modulation of [99mTc]Tc-iPSMA preparation conditions reduces radiochemical species heterogeneity and supports a single-vial cold-kit formulation
Article References: Chillard, J., Stamboul, L., Torchio, J., Rubira, L., & FERSING, C. (2026). Modulation of [99mTc]Tc-iPSMA preparation conditions reduces radiochemical species heterogeneity and supports a single-vial cold-kit formulation. Frontiers in Nuclear Medicine, 6, 1980206. https://doi.org/10.3389/fnume.2026.1980206
Image Credits: AI Generated
DOI: 10.3389/fnume.2026.1980206
Keywords: technetium-99m, iPSMA, HYNIC, cold-kit formulation, radiochemistry, radiolabeling, radiochemical purity, radio-HPLC, radio-TLC, prostate-specific membrane antigen, mannitol, tricine, EDDA, sodium acetate buffer, radiopharmaceuticals, chromatographic heterogeneity
News Source: Ophelia Keating. (November 20, 2026). Optimized Radiolabeling Improves iPSMA Homogeneity and Supports Single Vial Cold Kit Formulation. Scienmag.



